Drug Trial Radar · NCT00537394
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Jan 2008
Primary completion
May 2012
Study completion Apr 2013
Sponsor
- Sponsor type
- NIH
- Collaborators
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- First posted
- Oct 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit of adding a nucleoside reverse transcriptase inhibitor (NRTI) to a new anti-HIV drug regimen for the suppression of HIV.
Conditions
- HIV Infections
Interventions
EnfuvirtideDrug
90mg subcutaneously twice daily
RaltegravirDrug
400 mg twice daily
DarunavirDrug
Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
TipranavirDrug
Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
EtravirineDrug
Two 100-mg tablets twice daily
MaravirocDrug
Dosage dependent on regimen in which maraviroc is included
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study TreatmentTime frame: From study entry to end of Week 48 evaluation window
Locations
64 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Therapeutics CRS
Birmingham, Alabama
Miller Children's Hosp. Long Beach CA NICHD CRS
Long Beach, California
University of Southern California CRS
Los Angeles, California
Usc La Nichd Crs
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
Los Angeles, California
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California
UCSD Antiviral Research Center CRS
San Diego, California
Ucsf Hiv/Aids Crs
San Francisco, California
Univ. of California San Francisco NICHD CRS
San Francisco, California
University of Colorado Hospital CRS
Aurora, Colorado
Denver Public Health CRS
Denver, Colorado
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia
Children's National Med. Ctr. ATN CRS
Washington D.C., District of Columbia
Howard Univ. Washington DC NICHD CRS
Washington D.C., District of Columbia
Pediatric Perinatal HIV Clinical Trials Unit CRS
Miami, Florida
The Ponce de Leon Center CRS
Atlanta, Georgia
Northwestern University CRS
Chicago, Illinois
Rush University CRS
Chicago, Illinois
Tulane Univ. New Orleans NICHD CRS
New Orleans, Louisiana
IHV Baltimore Treatment CRS
Baltimore, Maryland
Johns Hopkins University CRS
Baltimore, Maryland
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts
Bmc Actg Crs
Boston, Massachusetts
Boston Medical Center Ped. HIV Program NICHD CRS
Boston, Massachusetts
Beth Israel Deaconess Med. Ctr., ACTG CRS
Boston, Massachusetts
Wayne State Univ. CRS
Detroit, Michigan
Henry Ford Hosp. CRS
Detroit, Michigan
Washington University Therapeutics (WT) CRS
St Louis, Missouri
Cooper Univ. Hosp. CRS
Camden, New Jersey
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey
Rutgers - New Jersey Medical School CRS
Newark, New Jersey
Weill Cornell Chelsea CRS
New York, New York
NY Univ. HIV/AIDS CRS
New York, New York
Nyu Ny Nichd Crs
New York, New York
Metropolitan Hosp. NICHD CRS
New York, New York
Columbia P&S CRS
New York, New York
Columbia IMPAACT CRS
New York, New York
Harlem ACTG CRS
New York, New York
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.